Between them, there is a negative functional cross-talk, thus A2A AR antagonists make A3 AR responsive to endogenous adenosine, reinforcing the therapeutic interest of A2A AR antagonists to fight AD [263]. This evidence concerns the gene ADORA3 and Alzheimer disease.